Heart failure & cardiomyopathies
Hemodynamic changes in response to GLP-1 treatment in ICD and CRT patients: insights from HeartLogic sensor data
Authors' conclusion
GLP-1RA initiation was associated with measurable changes in device-derived physiology.
Study context
- Population
- Danish patients with implantable cardiac devices (ICD and CRT)matched cohort
- Participants
- 666 patients
- Exposure
- GLP-1RA initiation vs no GLP-1RA
- GLP-1RAn = 111
- Controlsn = 555reference
- Outcome
- Changes in heart rate and thoracic impedance (device sensor data)
- Follow-up
- 30 days before to 30 days after initiation
Methodological detailsmatched 1:5 by sex and age, nationwide, prespecified subgroup analyses
- Matched 1:5 by sex and age
- Nationwide
- Prespecified subgroup analyses
Main finding
As reported in the abstract
GLP-1RA vs ControlsAdjusted difference, bpm (95% CI)P value
Night heart rate
2.12(1.38–2.87)
P < 0.01Daily heart rate
1.46(0.65–2.06)
P < 0.01GLP-1RA vs ControlsAdjusted difference, Ω (95% CI)P value
Thoracic impedance
0.66(0.17–1.15)
P < 0.01Observational data: associations, not effects.
Further findings
S1 amplitude · 30 days after initiation
- S1 amplitude decreased after GLP-1RA initiation (−0.09 mG; 95% CI, −0.14 to −0.04)
- P < 0.01
Heart rate by semaglutide dose level
- Stepwise HR increase across semaglutide dose levels; average increase per dose escalation
- 2.5 bpm
Heart failure and reduced ejection fraction (HFrEF) subgroup (GLP-1RA n = 80)
- Findings directionally consistent in HFrEF, no evidence of effect modification
- Prespecified subgroup analysis
Original publication
Hemodynamic changes in response to GLP-1 treatment in ICD and CRT patients: insights from HeartLogic sensor data. Eur J Heart Fail. Published 16 April 2026. doi:10.
Summarised from the published abstract; every number is checked against it